A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer (HARMONi-3)
- Sponsor:
- Summit Therapeutics
- Sponsor Study ID:
- SMT112-3003
- CTO #:
- 103876
- NCT Number:
- NCT05899608
- Phase:
- III
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Lung
- Study Objectives:
- To compare overall survival (OS) between ivonescimab combined with carboplatin and paclitaxel or nab-paclitaxel versus pembrolizumab combined with carboplatin and paclitaxel or nab-paclitaxel
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Alexander, Mariam, at alexanma@musc.edu .
- Study Coordinator, Morgan, Shelby, at morshelb@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina